

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 March 2005 (24.03.2005)

PCT

(10) International Publication Number
WO 2005/026201 A1

(51) International Patent Classification⁷: **C07K 14/025**,
C12N 5/10

(21) International Application Number:
PCT/GB2004/003880

(22) International Filing Date:
10 September 2004 (10.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/502,514 12 September 2003 (12.09.2003) US

(71) Applicants (for all designated States except US):
RENEURON LIMITED [GB/GB]; 10 Nugent Road,
Surrey Research Park, Guildford, Surrey GU2 7AF (GB).
LUDWIG INSTITUTE FOR CANCER RESEARCH
[US/US]; 605 3rd Avenue, 33rd Floor, New York, NY

10158 (US). **DANA FARBER CANCER INSTITUTE**
[US/US]; 44 Binney Street, Boston, MA 02115 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ROBERTS, Thomas** [US/US]; Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115 (US). **GJOERUP, Ole** [DK/US]; Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115 (US). **JAT, Parmjit** [GB/US]; Ludwig Institute for Cancer Research, 605 3rd Avenue, 33rd Floor, New York, NY 10158 (US). **COTSIKI, Marina** [GR/US]; Ludwig Institute for Cancer Research, 605 3rd Avenue, 33rd Floor, New York, NY 10158 (US).

(74) Agent: **GILL JENNINGS & EVERY**; Broadgate House,
7 Eldon Street, London EC2M 7LH (GB).



(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,

[Continued on next page]

(54) Title: IMMORTALISATION OF MAMMALIAN CELLS AND THERAPEUTIC APPLICATIONS OF SAID CELLS

b
SV40
BKV
JCV
BPV
K11happ
PvY

(57) Abstract: Genomic instability in T-antigen expressing cells can be overcome by modifying the gene expressing T-antigen so that it lacks Bub1 binding. Stable cell lines can be produced by incorporation of the modified T-antigen gene, preferably together with the catalytic sub-unit of the telomerase construct.





KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
- *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *with international search report*